Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

vTv Therapeutics (VTVT) Cash from Financing Activities (2016 - 2025)

vTv Therapeutics (VTVT) has disclosed Cash from Financing Activities for 12 consecutive years, with -$321000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities changed N/A to -$321000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $77.4 million through Dec 2025, up 47.21% year-over-year, with the annual reading at $77.4 million for FY2025, 47.21% up from the prior year.
  • Cash from Financing Activities hit -$321000.0 in Q4 2025 for vTv Therapeutics, down from $77.8 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $77.8 million in Q3 2025 to a low of -$321000.0 in Q4 2025.
  • Historically, Cash from Financing Activities has averaged $11.5 million across 5 years, with a median of $4.4 million in 2022.
  • Biggest YoY gain for Cash from Financing Activities was 4711.72% in 2023; the steepest drop was 107.69% in 2023.
  • Year by year, Cash from Financing Activities stood at $266000.0 in 2021, then soared by 1278.57% to $3.7 million in 2022, then plummeted by 107.69% to -$282000.0 in 2023, then skyrocketed by 973.4% to $2.5 million in 2024, then crashed by 113.03% to -$321000.0 in 2025.
  • Business Quant data shows Cash from Financing Activities for VTVT at -$321000.0 in Q4 2025, $77.8 million in Q3 2025, and -$42000.0 in Q2 2025.